Infection by Trichosporon Inkin in Lung Transplant: Rare Infection, or Not So Rare?

The incidence of invasive fungal infections has increased in recent years among transplant patients, with Trichosporon inkin being a rare but relevant etiological agent. This study examines the experience of our multidisciplinary lung transplant unit in the diagnosis and treatment of 6 cases of T. inkin infection in transplant patients from 2016 to 2023.

Impact of Telomere Shortening on Post-transplant Outcomes in Interstitial Lung Disease.

Shortened telomere length (STL) is associated with increased rates of interstitial lung diseases, malignancy, hematological disorders, and immunosuppressive treatment toxicities. In this single-center retrospective study, we aim to determine whether patients with interstitial lung diseases who have STL, as determined by quantitative PCR of buccal epithelial cells, exhibit worse post-transplant outcomes compared to recipients with normal telomere length. In our series of 26 patients, STL was associated with a higher incidence of chronic kidney disease following lung transplantation (100% vs 55%, P = .

Influence of Cytomegalovirus on the Survival of Cytomegalovirus-Seropositive Lung Transplant.

Background: The primary aim of this study was to analyze the survival of patients undergoing lung transplant (LT) with cytomegalovirus (CMV)-positive serologies at the time of transplantation, according to the presence of CMV events and according to the severity of these events. The secondary objective was to assess whether there are differences in the incidence of chronic lung allograft dysfunction (CLAD) according to the presence of these events.

Methods: This was an observational, single-center, retrospective study.

Antithymocyte Globulin Treatment for Chronic Lung Allograft Dysfunction in Lung Transplant Recipients: Experience From a National Reference Transplant Center.

Background: Chronic lung allograft dysfunction (CLAD) is the leading cause of mortality after the first year of transplantation and treatments can have little impact on CLAD progression in some cases. The objective of this study was to evaluate the effectiveness and safety of antithymocyte globulin (ATG) in lung transplant recipients with CLAD.

Methods: We reviewed all patients from our center that had undergone a lung transplant between 2008 and 2019 and selected those with CLAD who were treated with ATG.